Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)

NCT07219121 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT07219121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
October 7, 2025
Completion date
May 31, 2027
Enrollment
20 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, immunoglobulin a (iga) nephropathy, kidney transplant, proteinuria